The Middle East and Africa bladder cancer diagnostics market is projected to register a substantial CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Market Segmentation: Middle East and Africa Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa) Industry Trends and Forecast to 2030 Some of the major factors contributing to the growth of the Middle East and Africa bladder cancer diagnostics market are: • Rising incidence of bladder cancer globally • Rising awareness for the early diagnosis of bladder cancer Market Players: Some of the key market players for the Middle East and Africa bladder cancer diagnostics market are listed below: • F. Hoffmann-La Roche Ltd • Merck KGaA • Thermo Fisher Scientific Inc. • Koninklijke Philips N.V. • Bio-Rad Laboratories, Inc. • Agilent Technologies, Inc. • FUJIFILM Corporation • CANON MEDICAL SYSTEMS CORPORATION • Siemens Healthcare GmbH • BD • Neusoft Corporation • Abbott • General Electric Company • Hologic • QIAGEN • Cepheid. • Ambu A/S • Time Medical Holding. • MinFound Medical Systems Co., Ltd.

1 INTRODUCTION 26 1.1 OBJECTIVES OF THE STUDY 26 1.2 MARKET DEFINITION 26 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET 26 1.4 CURRENCY AND PRICING 27 1.5 LIMITATIONS 28 1.6 MARKETS COVERED 28 2 MARKET SEGMENTATION 30 2.1 MARKETS COVERED 30 2.2 GEOGRAPHICAL SCOPE 31 2.3 YEARS CONSIDERED FOR THE STUDY 32 2.4 DBMR TRIPOD DATA VALIDATION MODEL 33 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36 2.6 MULTIVARIATE MODELLING 37 2.7 TEST TYPE SEGMENT LIFELINE CURVE 37 2.8 MARKET END USER COVERAGE GRID 38 2.9 DBMR MARKET POSITION GRID 39 2.10 VENDOR SHARE ANALYSIS 40 2.11 SECONDARY SOURCES 41 2.12 ASSUMPTIONS 41 3 EXECUTIVE SUMMARY 42 4 PREMIUM INSIGHTS 44 4.1 PESTLE ANALYSIS 45 4.2 PORTER'S FIVE FORCES MODEL 46 5 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47 6 REGULATORY FRAMEWORK 49 7 MARKET OVERVIEW 50 7.1 DRIVERS 52 7.1.1 RISING INCIDENCE OF BLADDER CANCER MIDDLE EAST & AFRICALY 52 7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 52 7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 53 7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 53 7.2 RESTRAINTS 54 7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 54 7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 54 7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 54 7.3 OPPORTUNITIES 55 7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 55 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 55 7.3.3 INCREASE IN THE GERIATRIC POPULATION 56 7.4 CHALLENGES 56 7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 56 7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 57 8 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 58 8.1 OVERVIEW 59 8.2 CYSTOSCOPY 62 8.3 URINE LAB TEST 62 8.3.1 URINE CYTOLOGY 64 8.3.2 URINALYSIS 64 8.3.3 URINE TUMOR MARKER TEST 64 8.3.4 URINE CULTURE 64 8.3.5 OTHERS 64 8.4 BIOPSY 64 8.5 IMAGING TEST 65 8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 66 8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 66 8.5.3 ULTRASOUND 66 8.5.4 INTRAVENOUS PYELOGRAM (IVP) 67 8.6 OTHERS 67 9 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 68 9.1 OVERVIEW 69 9.2 STAGE IV 72 9.3 STAGE III 72 9.4 STAGE II 73 9.5 STAGE I 74 10 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 76 10.1 OVERVIEW 77 10.2 TRANSITIONAL CELL BLADDER CANCER 80 10.3 SQUAMOUS CELL BLADDER CANCER 81 10.4 OTHER CANCER TYPES 82 11 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 83 11.1 OVERVIEW 84 11.2 HOSPITAL 87 11.3 DIAGNOSTIC IMAGING CENTERS 87 11.4 CANCER RESEARCH INSTITUTES 88 11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 89 11.6 ASSOCIATED LABS 90 12 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 91 12.1 OVERVIEW 92 12.2 DIRECT TENDER 95 12.3 RETAIL SALES 95 13 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 97 13.1 MIDDLE EAST AND AFRICA 98 13.1.1 SOUTH AFRICA 105 13.1.2 SAUDI ARABIA 107 13.1.3 U.A.E 109 13.1.4 EGYPT 111 13.1.5 ISRAEL 113 13.1.6 REST OF MIDDLE EAST AND AFRICA 115 14 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 116 14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 116 15 SWOT ANALYSIS 117 16 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET 118 16.1 F. HOFFMANN- LA ROCHE LTD 118 16.1.1 COMPANY SNAPSHOT 118 16.1.2 REVENUE ANALYSIS 118 16.1.3 COMPANY SHARE ANALYSIS 119 16.1.4 PRODUCT PORTFOLIO 119 16.1.5 RECENT DEVELOPMENTS 119 16.2 MERCK KGAA 120 16.2.1 COMPANY SNAPSHOT 120 16.2.2 REVENUE ANALYSIS 120 16.2.3 COMPANY SHARE ANALYSIS 121 16.2.4 PRODUCT PORTFOLIO 121 16.2.5 RECENT DEVELOPMENT 121 16.3 THERMO FISHER SCIENTIFIC INC 122 16.3.1 COMPANY SNAPSHOT 122 16.3.2 REVENUE ANALYSIS 122 16.3.3 COMPANY SHARE ANALYSIS 123 16.3.4 PRODUCT PORTFOLIO 123 16.3.5 RECENT DEVELOPMENT 123 16.4 KONINLIJKE PHILIPS N.V 124 16.4.1 COMPANY SNAPSHOT 124 16.4.2 REVENUE ANALYSIS 124 16.4.3 COMPANY SHARE ANALYSIS 125 16.4.4 PRODUCT PORTFOLIO 125 16.4.5 RECENT DEVELOPMENT 125 16.5 BIO-RAD LABORATORIES, INC 126 16.5.1 COMPANY SNAPSHOT 126 16.5.2 COMPANY SNAPSHOT 126 16.5.3 COMPANY SHARE ANALYSIS 127 16.5.4 PRODUCT PORTFOLIO 127 16.5.5 RECENT DEVELOPMENT 127 16.6 ABBOTT 128 16.6.1 COMPANY SNAPSHOT 128 16.6.2 REVENUE ANALYSIS 128 16.6.3 PRODUCT PORTFOLIO 129 16.6.4 RECENT DEVELOPMENT 129 16.7 AGILENT TECHNOLOGIES, INC 130 16.7.1 COMPANY SNAPSHOT 130 16.7.2 REVENUE ANALYSIS 130 16.7.3 PRODUCT PORTFOLIO 131 16.7.4 RECENT DEVELOPMENT 131 16.8 AMBU A/S 132 16.8.1 COMPANY SNAPSHOT 132 16.8.2 REVENUE ANALYSIS 132 16.8.3 PRODUCT PORTFOLIO 133 16.8.4 RECENT DEVELOPMENT 133 16.9 BD 134 16.9.1 COMPANY SNAPSHOT 134 16.9.2 REVENUE ANALYSIS 134 16.9.3 PRODUCT PORTFOLIO 135 16.9.4 RECENT DEVELOPMENT 135 16.10 CANON MEDICAL SYSTEMS CORPORATION 136 16.10.1 COMPANY SNAPSHOT 136 16.10.2 REVENUE ANALYSIS 136 16.10.3 PRODUCT PORTFOLIO 137 16.10.4 RECENT DEVELOPMENT 137 16.11 CEPHEID 138 16.11.1 COMPANY SNAPSHOT 138 16.11.2 REVENUE ANALYSIS 138 16.11.3 PRODUCT PORTFOLIO 139 16.11.4 RECENT DEVELOPMENTS 139 16.12 FUJIFILM CORPORATION 140 16.12.1 COMPANY SNAPSHOT 140 16.12.2 REVENUE ANALYSIS 140 16.12.3 PRODUCT PORTFOLIO 141 16.12.4 RECENT DEVELOPMENTS 141 16.13 GENERAL ELECTRIC COMPANY 142 16.13.1 COMPANY SNAPSHOT 142 16.13.2 REVENUE ANALYSIS 142 16.13.3 PRODUCT PORTFOLIO 143 16.13.4 RECENT DEVELOPMENTS 143 16.14 HOLOGIC INC 144 16.14.1 COMPANY SNAPSHOT 144 16.14.2 REVENUE ANALYSIS 144 16.14.3 PRODUCT PORTFOLIO 145 16.14.4 RECENT DEVELOPMENT 145 16.15 ILLUMINA INC 146 16.15.1 COMPANY SNAPSHOT 146 16.15.2 REVENUE ANALYSIS 146 16.15.3 PRODUCT PORTFOLIO 147 16.15.4 RECENT DEVELOPMENTS 147 16.16 MINFOUND MEDICAL SYSTEMS CO 148 16.16.1 COMPANY SNAPSHOT 148 16.16.2 PRODUCT PORTFOLIO 148 16.16.3 RECENT DEVELOPMENTS 148 16.17 NEUSOFT CORPORATION 149 16.17.1 COMPANY SNAPSHOT 149 16.17.2 COMPANY SNAPSHOT 149 16.17.3 PRODUCT PORTFOLIO 150 16.17.4 RECENT DEVELOPMENT 150 16.18 QIAGEN 151 16.18.1 COMPANY SNAPSHOT 151 16.18.2 REVENUE ANALYSIS 151 16.18.3 PRODUCT PORTFOLIO 152 16.18.4 RECENT DEVELOPMENT 152 16.19 SIEMENS HEALTHCARE GMBH 153 16.19.1 COMPANY SNAPSHOT 153 16.19.2 REVENUE ANALYSIS 153 16.19.3 PRODUCT PORTFOLIO 154 16.19.4 RECENT DEVELOPMENT 155 16.20 TIME MEDICAL HOLDING 156 16.20.1 COMPANY SNAPSHOT 156 16.20.2 PRODUCT PORTFOLIO 156 16.20.3 RECENT DEVELOPMENTS 156 17 QUESTIONNAIRE 157 18 RELATED REPORTS 160